Share This Page
Drug Price Trends for ODEFSEY TABLET
✉ Email this page to a colleague
Average Pharmacy Cost for ODEFSEY TABLET
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ODEFSEY TABLET | 61958-2101-01 | 130.45597 | EACH | 2026-07-22 |
| ODEFSEY TABLET | 61958-2101-01 | 130.38452 | EACH | 2026-06-17 |
| ODEFSEY TABLET | 61958-2101-01 | 130.34195 | EACH | 2026-05-20 |
| ODEFSEY TABLET | 61958-2101-01 | 130.35091 | EACH | 2026-01-01 |
| ODEFSEY TABLET | 61958-2101-01 | 124.26207 | EACH | 2025-12-17 |
| ODEFSEY TABLET | 61958-2101-01 | 124.25527 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for ODEFSEY Tablet
What is ODEFSEY, and what is its market positioning?
ODEFSEY is an oral combination therapy used to treat chronic hepatitis B virus (HBV) infection. It contains a fixed-dose combination of tenofovir alafenamide (TAF) and emtricitabine (FTC).
Manufactured by Gilead Sciences, ODEFSEY received approval from the U.S. Food and Drug Administration (FDA) in November 2020. Its approval expanded options for patients requiring long-term antiviral therapy with a simplified regimen. ODEFSEY is positioned as an alternative to standalone tenofovir and emtricitabine formulations, offering similar efficacy with potentially improved safety profiles.
Market penetration has been influenced by its positioning among existing nucleos(t)ide analogs and the ongoing shift toward combination therapies to improve adherence.
How is the current market landscape for hepatitis B treatments structured?
The hepatitis B treatment market includes multiple drug classes:
- Nucleos(t)ide analogs (NAs): Entecavir, tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and lamivudine.
- Interferons: Pegylated interferon-alpha.
- Combination therapies: Emerging, with focus on simplifying regimens and minimizing resistance.
The global hepatitis B therapy market was valued at approximately USD 1.2 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of roughly 4.8% through 2028 [1].
What is the competitive landscape for ODEFSEY?
Major competitors include:
- Gilead’s Vemlidy (TDF-based) and Biktarvy (a tri-combination containing TAF).
- Merck’s Zepatier (elbasvir/grazoprevir).
- Novartis’ hepatitis B agents (still under development).
ODEFSEY competes directly with Gilead’s Vemlidy, which has broader indications and established market share for chronic HBV treatment.
What are the pricing components and current prices?
Pricing varies by region and healthcare system. In the U.S., the wholesale acquisition cost (WAC) for ODEFSEY is approximately USD 4,500 per month [2]. Insurance reimbursement levels tend to reduce patient's out-of-pocket expenses.
Comparative pricing:
| Drug | Indication | Approximate Monthly WAC | Approval Year |
|---|---|---|---|
| ODEFSEY (Gilead) | Chronic HBV | USD 4,500 | 2020 |
| Vemlidy (Gilead) | Chronic HBV | USD 3,200 | 2018 |
| Epivir HBV | Chronic HBV | USD 250/month (generic) | 1988 |
ODEFSEY’s premium pricing is due to the combination formulation and recent market entry.
What are the price projections for the next 3–5 years?
Factors influencing price forecasts include patent protection, competitive pressures, and reimbursement policies.
Projected trends:
- Short-term (1–2 years): Remain stable at current levels amid limited generic competition.
- Mid-term (3–5 years): Prices could decline by approximately 10–15% due to potential biosimilar or generic entrants where patent expiry occurs, or if Gilead adjusts pricing strategies [3].
Assumptions:
- Patent expiry for ODEFSEY expected around 2035.
- Gilead maintains a dominant position, with no significant price reductions prior to that due to brand loyalty and patent protections.
- Competitive alternatives remain limited.
Potential price trajectory:
| Year | Estimated Price Range (USD/month) | Notes |
|---|---|---|
| 2023 | USD 4,500 | Current price |
| 2024–2025 | USD 4,250–4,350 | Slight reduction assumed |
| 2026–2030 | USD 3,800–4,000 | Price pressure increases with competition potential |
What are the key factors influencing pricing?
- Patent status: Protects current pricing until at least 2035.
- Competitive launches: New HBV agents or simplified regimens could pressure prices downward.
- Reimbursement policies: Insurance coverage influences consumer prices versus list prices.
- Market penetration: As market share increases, Gilead may leverage volume to offset price reductions.
Conclusion
The current market for ODEFSEY shows limited immediate price declines but anticipates modest reductions over the next five years. Gilead's position as the sole provider limits aggressive pricing adjustments early, yet patent expiration and new competition may materially influence prices post-2035.
Key Takeaways
- ODEFSEY’s current WAC is approximately USD 4,500/month in the U.S.
- It competes primarily with Vemlidy, which is priced lower.
- Market growth driven by increasing global HBV prevalence and preference for combination therapies.
- Price reductions are expected to occur gradually as patent protections near expiry.
- Potential entry of biosimilars or generics could prompt earlier adjustments.
FAQs
1. When will ODEFSEY's patent protection expire?
It is expected around 2035, based on current patent filings and data.
2. Are there any approved biosimilars or generics?
Not yet. Biosimilars for TAF and FTC are not available, but generic versions of individual components may eventually enter the market post-patent expiry.
3. How does ODEFSEY’s price compare globally?
Pricing varies significantly; in Europe, prices tend to be lower, often reflecting local reimbursement and healthcare policies.
4. Will competition from new HBV drugs influence ODEFSEY’s price?
Yes, especially if novel therapies reduce the demand for existing nucleoside/nucleotide analogs.
5. How might insurance coverage affect patient out-of-pocket costs?
Coverage levels can significantly reduce out-of-pocket burdens, potentially influencing demand and market dynamics.
References
[1] MarketsandMarkets. (2022). Hepatitis B Treatment Market – Global Forecast to 2028.
[2] Gilead Sciences. (2022). Product pricing and reimbursement.
[3] IQVIA. (2022). Pharmaceutical Market Outlook.
More… ↓
